# Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

> **NCT05038592** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Myelodysplastic/Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Decitabine
- **BIOLOGICAL:** Tagraxofusp-erzs

## Key facts

- **NCT ID:** NCT05038592
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-04
- **Primary completion:** 2027-01-29
- **Final completion:** 2027-01-29
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038592, "Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05038592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*